Bausch Health Cos Inc. (NYSE:BHC) Receives $7.42 Average Price Target from Analysts

Bausch Health Cos Inc. (NYSE:BHC) has been given an average recommendation of “Reduce” by the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a hold recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $7.42.

Several equities analysts recently commented on BHC shares. Royal Bank Of Canada upped their target price on Bausch Health Cos from $8.50 to $10.00 and gave the company a “sector perform” rating in a research note on Friday, May 2nd. Wall Street Zen downgraded shares of Bausch Health Cos from a “buy” rating to a “hold” rating in a research note on Saturday, May 10th.

Insider Buying and Selling

In other news, Director John Paulson purchased 754,134 shares of the company’s stock in a transaction on Tuesday, June 10th. The stock was bought at an average cost of $5.05 per share, for a total transaction of $3,808,376.70. Following the completion of the purchase, the director now directly owns 27,193,169 shares of the company’s stock, valued at $137,325,503.45. The trade was a 2.85% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last ninety days, insiders have bought 6,352,667 shares of company stock valued at $35,870,767. 8.05% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Bausch Health Cos

Several hedge funds and other institutional investors have recently modified their holdings of the company. Principal Securities Inc. increased its position in Bausch Health Cos by 39.7% during the 4th quarter. Principal Securities Inc. now owns 19,220 shares of the company’s stock worth $155,000 after purchasing an additional 5,464 shares in the last quarter. Handelsbanken Fonder AB grew its stake in Bausch Health Cos by 18.4% during the fourth quarter. Handelsbanken Fonder AB now owns 65,100 shares of the company’s stock worth $525,000 after buying an additional 10,100 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Bausch Health Cos by 1.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,284,036 shares of the company’s stock worth $10,375,000 after acquiring an additional 14,558 shares in the last quarter. Aigen Investment Management LP acquired a new stake in shares of Bausch Health Cos in the fourth quarter worth $180,000. Finally, Raymond James Financial Inc. purchased a new position in shares of Bausch Health Cos in the 4th quarter valued at $180,000. 78.65% of the stock is owned by institutional investors and hedge funds.

Bausch Health Cos Stock Performance

Shares of BHC opened at $6.17 on Friday. Bausch Health Cos has a fifty-two week low of $3.96 and a fifty-two week high of $9.85. The stock has a fifty day moving average of $4.98 and a two-hundred day moving average of $6.35. The company has a market capitalization of $2.28 billion, a PE ratio of -56.09 and a beta of 0.28.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.